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A Case of a False-Positive Anti-Myeloperoxidase Antibody ELISA 
in a Patient with Hypothyroidism
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We present a case of a false-positive anti-myeloperoxidase (MPO) antibody result on 
an ELISA in a patient with anti-thyroid microsomal antibody (TMA)-positive hypo-
thyroidism. A 41-year-old woman presented with dyspnea on exertion. The initial eval-
uation revealed pericardial effusion associated with hypothyroidism. In addition, mi-
croscopic hematuria with normal renal function and positive cytoplasmic anti-neu-
trophil cytoplasmic antibodies (c-ANCA) on immunofluorescent assay were found. In 
further evaluation, elevated anti-TMA and MPO antibodies by ELISA. While no defi-
nite signs of vasculitis were present, the clinical state improved with thyroid hormone 
replacement and diuretics. Anti-MPO antibody was still positive in the follow-up tests, 
and microscopic hematuria persisted. On the basis of previous reports that thyroid per-
oxidase and MPO molecules contain cross-reactive epitopes that are exposed in denatu-
rated molecules, we suggest that in a patient with anti-TMA-positive hypothyroidism, 
anti-MPO antibody might also be positive on ELISA without clinical signs of vasculitis.
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INTRODUCTION
　Anti-neutrophil cytoplasmic antibody (ANCA) is a use-
ful autoantibody in the diagnosis of idiopathic small-vessel 
vasculitides (SVV). Its target antigens include proteinase- 
3 (PR3), myeloperoxidase (MPO), elastase, lactoferrin, lac-
toperoxidase, lysozyme, azurocidin, and cathepsin G. Anti- 
MPO is particularly known as an important marker for the 
diagnosis of vasculitis, such as idiopathic crescentic glome-
rulonephritis and microscopic polyarteritis nodosa (MPA).
1 
The ANCA tests include the indirect immunofluorescence 
assay (IFA) in which neutrophils are fixed on the slide 
(ANCA IFA) and the enzyme-linked immunosorbent assay 
(ELISA) using individual antigens (i.e., anti-MPO ELISA, 
anti-PR3 ELISA).
　A previous case report presented an anti-MPO antibody- 
positive patient who was also positive for the anti-thyroid 
microsomal antibody (anti-TMA).
2 A recent study reported 
that thyroid peroxidase (TPO) is a major antigen of anti- 
TMA.
3 According to the observation of considerable simila-
rity in the peptide sequences of TPO and MPO,
4 a possible 
cross-reactivity between the anti-TPO antibody and the 
anti-MPO antibody was studied. That study used synthetic 
peptides for MPO and TPO, and found that the denatura-
tion exposed cross-reactive epitopes on those antigens, 
which might lead to a false-positive result in the solid phase 
of the ELISA assay.
5 There was a case report in which a pa-
tient with anti-TPO-positive thyrotoxicosis also had anti- 
MPO-positive vasculitis,
6 but false-positivity has not been 
reported in Korea. Here we present a case of a false-positive 
anti-MPO ELISA result in a patient with anti-TPO-positive 
hypothyroidism.
CASE REPORT
　Patient: Age 41, female
　Chief complaints: Dyspnea and abdominal pain
　Present medical history: Epigastric pain and dyspnea 
had developed 2 days previously, which led her to visit a 
neighborhood clinic, where pleural and pericardial effu-
sion were confirmed by abdominal CT. She was then trans-
ferred to our hospital.49
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FIG. 1. Clinical status and laboratory findings of ANCA, anti-MPO
antibody, and anti-TMA. C-ANCA: cytoplasmic anti-neutrophil 
cytoplasmic antibodies, Anti-TMA: anti-thyroid microsomal anti-
body, Anti-MPO Ab: anti-myeloperoxidase antibody.
　Past medical history: No specific findings.
　Family history: No specific findings.
　Findings on physical examination: Vital signs at the time 
of the visit were as follows: blood pressure, 91/65 mmHg; 
heart rate, 97/min; body temperature, 36.5
oC; and respira-
tory rate, 16/min. The patient appeared acutely ill, with 
presentation of a swollen face and bilateral jugular venous 
dilatation. Heart sounds were reduced, and edema was 
present in both legs. 
　Laboratory findings: A routine blood test at the initial 
visit revealed a white blood cell (WBC) count of 13,030/uL 
(normal: 4,800-10,800/uL), hemoglobin of 13.6 g/dL (normal: 
13-18 g/dL), and platelets of 313,000/uL (normal: 130,000- 
400,000/uL). C-reactive protein (CRP) was 3.37 mg/dL 
(normal: ＜0.5 mg/dL) by immunoturbidimetry. Serum 
chemistry analysis showed blood urea nitrogen (BUN) was 
31.0 mg/dL (normal: 6-20 mg/dL), creatinine was 0.61 mg/ 
dL (normal: 0.9-1.5 mg/dL), Na was 135 mmol/L (normal: 
136-146 mmol/L), and K was 4.3 mmol/L (normal: 3.3-5.1 
mmol/L). The following were found to be elevated: GOT, 56 
U/L (normal: ＜37 U/L); GPT, 56 U/L (normal: ＜41 U/L); 
ALP, 108 IU/L (normal: 35-129 IU/L); and GGT, 128 U/L 
(normal: 8-61 U/L). Total protein was 6.5 g/dL (normal: 
6.7-8.3 g/dL), and albumin was 3.5 g/dL (normal: 3.2-4.8 
g/dL). The urinalysis results were as follows: SG, 1.020 
(normal: 1.003-1.03); pH 5.5 (normal: 4.5-8.0); urine protein 
(−); urine glucose (±); red blood cell (RBC) count, many/ 
HPF; and WBC, many/HPF. Other readings included 
Pro-BNP of 10,550 pg/mL (normal: 0-194 pg/mL), CK-MB 
of 6.4 ng/ mL (normal: 0-3.6 ng/mL), and cardiac troponin 
I of 5.24 ng/mL (normal: 0-0.1 ng/mL). 
　Radiological findings: Simple chest X-ray showed an in-
creased cardiothoracic ratio. Echocardiography confirmed 
pericardial effusion, and the inferior vena cava was dilated. 
Abdominal ultrasonography also showed findings of dila-
tation of the hepatic vein and the inferior vena cava, along 
with a small amount of ascites. There was no sign of hepatic 
enlargement. Thyroid ultrasonography revealed diffuse 
bilateral goiter and benign nodules.
　Treatment and progress: The results of the post-admis-
sion thyroid function test were as follows: TSH, 9.1 uIU/mL 
(normal: 0.3-4 uIU/mL); free T4, 1.4 ng/dL (normal: 0.8-1.8 
ng/dL); T3, 0.4 ng/mL (normal: 0.6-1.9 ng/mL); and anti- 
TMA, 403.2 U/mL (normal: 0-60 U/mL). The patient was 
ANA (antinuclear antibody)-negative and ANCA IFA-po-
sitive [cytoplasmic pattern (C-ANCA), titer 1:20]. Anti- 
MPO ELISA and anti-PR3 ELISA titers were 449 AAU 
(normal: 0-150 AAU) and 56 AAU (normal: 0-150 AAU), res-
pectively. Renal function was normal with a BUN of 14.8 
mg/dL and a creatinine level of 0.62 mg/dL. The pericardial 
and pleural effusion fluid was thought to be related to hypo-
thyroidism, and levothyroxine treatment was started (0.025 
mg for the 1st week and 0.05 mg thereafter for 1 month). 
Diuretics (torsemide 20 mg and spironolactone 100 mg) 
were given upon admission for treatment of heart failure, 
and dyspnea improved. Echocardiography performed 2 
weeks later showed decrease in the pericardial effusion 
fluid. Urinalysis performed at the time of discharge showed 
RBC was 0-1/HPF, and the AST, ALP, CRP, and cTnI levels 
were reduced to normal.
　Urinalysis at 1 month after discharge revealed RBC was 
5-10/HPF, with persistent microscopic findings of hema-
turia. Other results included anti-MPO ELISA, 554 AAU; 
anti-TMA, 1046.2 U/mL; TSH, 0.03 uIU/mL; free T4, 5.3 
ng/dL; and T3, 2.9 ng/mL. Upon the findings, levothyroxine 
was discontinued. 
　At 3 months after discharge, urine RBC was 3-5/HPF. 
ANCA IFA was negative, with an anti-MPO ELISA titer 
of 849 AAU. Urinalysis at 11 months showed RBC was 3-5/ 
HPF, spot urine protein-to-creatinine ratio was 0.09, and 
anti-MPO ELISA was 639 AAU. Anti-TMA antibody was 
continuously elevated at 1236.3 U/mL (Fig. 1). Thyroid 
function was maintained normal with TSH of 4.3 uIU/mL, 
free T4 of 1.5 ng/dL, and T3 of 1.0 ng/mL. At 1 year after 
discharge, the patient has not shown any specific symp-
toms without drug treatment, and is still being closely 
monitored.
DISCUSSION
　ANCA is an autoimmune antibody that reacts to the cyto-
plasmic antigens in the neutrophils and monocytes.
7 Anti- 
MPO, a subtype of ANCA, is positive in patients with vascu-
litis (e.g., microscopic polyarteritis nodosa, Churg-Strauss 
syndrome)
8 and has been used as a diagnostic marker of 
such disease. TPO is known as a major antigen of TMA, and 
anti-TMA is a main autoantibody involved in autoimmune 
thyroiditis. There is a case report of a patient who was both 
anti-MPO- and anti-TPO-positive and had both vasculitis 50
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and thyroid disease.
6 The patient had Grave’s disease and 
anti-MPO-positive glomerulonephritis.
9 Whereas our pa-
tient in the present case was anti-TMA- and anti-MPO-pos-
itive and had hypothyroidism, she showed no symptoms 
leading to a clinical suspicion of vasculitis, despite the stea-
dily elevated anti-MPO level. There were findings of hypo-
thyroidism on the thyroid function test, and she was anti- 
TMA-positive. She also had positive results on the ANCA 
IFA and anti-MPO ELISA. The microscopic hematuria per-
sisted, but without clinical symptoms of vasculitis. The anti- 
MPO ELISA continued to be positive. Later, negative sero-
conversion of ANCA IFA was observed, but the anti-MPO 
ELISA remained positive. Anti-MPO and anti-TMA were 
continuously positive throughout the outpatient monitor-
ing over about 1 year, but no clinical findings conforming 
to vasculitis were found, except for the microscopic hema-
turia. Because renal biopsy was not performed initially 
when the microscopic hematuria and the positivity for ANCA 
and anti-MPO antibody was observed, we could not de-
termine whether the microscopic hematuria was caused by 
a glomerular lesion accompanied by vascular changes. 
Nonetheless, normal renal function was maintained with-
out proteinuria, and there were no findings to suggest vas-
culitis in other organs. Therefore, the possibility of vasculitis 
causing the hematuria appeared to be low. Furthermore, 
the initial ANCA IFA positivity was a C-ANCA pattern and 
might be unrelated to anti-MPO, which presents a peri-
nuclear pattern (P-ANCA). TPO is known as the major an-
tigen of TMA,
3 and there are reports of peptide sequence 
similarities between TPO and MPO.
4 In one study, anti- 
TPO and anti-MPO obtained from a patient with vasculitis 
and a patient with autoimmune thyroiditis, respectively, 
were put into reaction to the native TPO and MPO anti-
gens. The anti-TPO reacted to the native TPO antigen but 
not to the native MPO antigen. Likewise, the anti-MPO re-
acted to the native MPO antigen but not to the native TPO 
antigen. Notably, the two antibodies showed cross-reactivity 
when the synthetic TPO and MPO antigens were used. The 
reported peptide sequence homology between TPO and 
MPO was up to 88%. During synthesis, the antibodies ob-
tain a linear structure while the original peptide sequences 
are maintained. This configurational change exposes the 
cross-reactive epitopes.
5 The absence of cross-reactivity to 
the native antigens is attributable to 1) the native spatial 
configuration of the antigens in which the cross-reactive 
epitopes are not well exposed and 2) the possibility of the 
native configuration working as an epitope itself. This was 
confirmed by another study in which anti-MPO reacted to 
native MPO but not to denaturated MPO.
10 In ANCA IFA, 
patient serum is added to the neutrophils isolated from 
healthy donors. The fluorescent antigens are added, and 
the presence of ANCA is determined by using fluorescence 
microscopy. In other words, patient serum is added to na-
tive antigens. In ELISA, patient serum is added to the solid 
phase to which the MPO-specific antigens are attached. 
Then, the presence of ANCA is determined by absorbance 
and subsequently quantified. Here, unlike in the immuno-
fluorescence, patient serum is added to synthetic antigens. 
Use of antigens that have epitopes common to both MPO 
and TPO in ELISA might cause cross-reaction of anti-TPO 
to synthetic MPO. In this case, anti-TPO positivity might 
result in anti-MPO positivity. In the present case, the pa-
tient was negative for the ANCA IFA but positive for the 
anti-MPO ELISA, which suggests the possibility of false 
anti-MPO positivity. Because we did not perform a renal 
biopsy, however, it remains uncertain whether a minor glo-
merular lesion was present.
　In conclusion, when a patient is ANCA negative on IFA 
and is without clinical signs of vasculitis, but anti-MPO 
positive on ELISA, one should consider a possible cross-re-
activity of MPO to thyroid autoantibody. In this case, it may 
be necessary to test thyroid function and autoantibody to 
investigate a possible false ELISA positivity.
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